Compass Pathways stock took a hit in early June. Lykos Therapeutics just got some extremely bearish news from regulators. Regulators being skeptical about Lykos' medicine could be bad for Compass.

Compass is a market leader in real estate brokerage, showing strong growth and cost control despite a sluggish market. I expect the real estate market to improve as the Federal Reserve is likely to ...

Compass Inc (NYSE: COMP) shares are popping on Wednesday after an early dip sparked by dilution concerns amid the company's announcement of a $750 million offering of convertible senior notes due 2031 ...